Aurgalys Team
Selected Customers
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]

.:: Sensorion [ALSEN] ::.

Sensorion is a biopharmaceutical company, specializing in the development of drugs for inner ear disorders. Its lead product, SENS-111, is a Phase II-ready drug candidate for the treatment of vertigo and tinnitus. The company announced positive Phase Ib results confirming the safety and tolerability of SENS-111 in healthy volunteers. The company also develops SENS-218 for vestibular lesions. SENS-218 is a molecule from the setron class, a well known family of antiemetic drugs. A pilot study already conducted in patients with a different molecule of the same class demonstrated efficacy in preserving vestibular functions. SENS-218 is in late preclinical and a Phase II study could start as early as H2-2016.

The coverage was initiated Nov 24th, 2015

Our target price for Sensorion as of Nov 9th, 2017, is €7.70/ share.

From Nov 9th, 2017, Aurgalys analyst reports on Sensorion will be published in English and French

A partir du 9 novembre 2017, les rapports d’analyse d’Aurgalys sur Sensorion seront publiés en Français et en Anglais